What it is

Bremelanotide (also known historically as PT-141) is a melanocortin receptor agonist. Unlike PDE5 inhibitors, it does not primarily act via peripheral nitric oxide pathways; instead, it is thought to modulate central melanocortin pathways involved in sexual desire and arousal.

Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Why people use it

Clinically, bremelanotide is used for HSDD in the approved population. In non-medical settings, it is sometimes sought for libido effects outside labeled use, which increases risk because cardiovascular precautions and contraindications matter for this mechanism.

History and origin

Bremelanotide developed from melanocortin peptide research and earlier tanning-focused analog programs, with later clinical development focused on sexual desire outcomes rather than pigmentation. Its eventual approval reflects a defined clinical development pathway with placebo-controlled trials and a labeled safety profile.

How it works

Bremelanotide is a melanocortin receptor agonist with central nervous system activity. Its therapeutic hypothesis in HSDD is that melanocortin signaling influences motivational and arousal circuits. Because melanocortin receptors also participate in autonomic and cardiovascular regulation, transient blood pressure increases and other systemic effects are biologically plausible and reflected in labeling.

Evidence landscape

Evidence includes randomized controlled trials supporting modest average improvements in validated desire/distress endpoints in the indicated population, along with predictable tolerability limitations (notably nausea). As with many sexual medicine outcomes, effect sizes are variable and patient selection matters.

Safety reality

Bremelanotide has an FDA label with defined contraindications, warnings, and adverse reactions. Key safety themes include blood pressure effects, nausea, and the need to avoid use in certain cardiovascular contexts. Using non-pharmaceutical “PT-141” products introduces additional risks of incorrect dosing, impurities, and absence of medical screening.

References

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (2019). https://pubmed.ncbi.nlm.nih.gov/31599840/

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder (2019). https://pubmed.ncbi.nlm.nih.gov/31599847/

Vyleesi (bremelanotide) injection, prescribing information (FDA label PDF) (2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208470s000lbl.pdf

Bremelanotide efficacy and safety in premenopausal women with HSDD (ClinicalTrials.gov). https://clinicaltrials.gov/study/NCT02333071